FTC Clears AbbVie To Proceed With $10.1B ImmunoGen Buy
By Craig Clough · February 9, 2024, 5:07 PM EST
The 30-day waiting period for U.S. antitrust enforcers to review AbbVie's $10.1 billion purchase of ImmunoGen came and went without a move to deepen the investigation or challenge the deal, clearing...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login